| Montana Family Vision Care, Pc | |
|
2829 Great Northern Loop, Suite 100, Missoula, MT 59808-1752 | |
| (406) 542-6382 | |
| (406) 542-4773 |
| Full Name | Montana Family Vision Care, Pc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 2829 Great Northern Loop, Missoula, Montana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194908624 | NPI | - | NPPES |
| 0481423 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 671 (Montana) | Primary |
| Provider Name | Thomas D Hall |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922154731 PECOS PAC ID: 0547167033 Enrollment ID: I20031213000038 |
News Archive
Horrifying research out today in the Journal of Epidemiology and Community Health, suggest that one in 50 and one in 80 adults between the ages of 15 and 44 in London, Liverpool, and Brighton is an injecting drug user. And users are more likely to die of their habit in Brighton, finds the study.
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
Researchers at St. Jude Children's Research Hospital have discovered the way toxic proteins linked to the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) incapacitate membrane-less organelles inside cells.
› Verified 3 days ago
| Provider Name | Kellie Hadnot |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1093979619 PECOS PAC ID: 4082781513 Enrollment ID: I20100629000900 |
News Archive
Horrifying research out today in the Journal of Epidemiology and Community Health, suggest that one in 50 and one in 80 adults between the ages of 15 and 44 in London, Liverpool, and Brighton is an injecting drug user. And users are more likely to die of their habit in Brighton, finds the study.
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
Researchers at St. Jude Children's Research Hospital have discovered the way toxic proteins linked to the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) incapacitate membrane-less organelles inside cells.
› Verified 3 days ago
| Provider Name | Haley A Owens |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1134672751 PECOS PAC ID: 1052689585 Enrollment ID: I20170623002466 |
News Archive
Horrifying research out today in the Journal of Epidemiology and Community Health, suggest that one in 50 and one in 80 adults between the ages of 15 and 44 in London, Liverpool, and Brighton is an injecting drug user. And users are more likely to die of their habit in Brighton, finds the study.
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
Researchers at St. Jude Children's Research Hospital have discovered the way toxic proteins linked to the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) incapacitate membrane-less organelles inside cells.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Montana Family Vision Care, Pc 2829 Great Northern Loop, Suite 100, Missoula, MT 59808-1752 Ph: (406) 542-6382 | Montana Family Vision Care, Pc 2829 Great Northern Loop, Suite 100, Missoula, MT 59808-1752 Ph: (406) 542-6382 |
News Archive
Horrifying research out today in the Journal of Epidemiology and Community Health, suggest that one in 50 and one in 80 adults between the ages of 15 and 44 in London, Liverpool, and Brighton is an injecting drug user. And users are more likely to die of their habit in Brighton, finds the study.
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
Researchers at St. Jude Children's Research Hospital have discovered the way toxic proteins linked to the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) incapacitate membrane-less organelles inside cells.
› Verified 3 days ago
Mark Wayne Mutter Ii, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 700 W Kent Ave, Missoula, MT 59801 Phone: 406-541-3937 Fax: 406-541-3811 | |
Thomas R Ferguson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2510 S Reserve St, Missoula, MT 59801 Phone: 406-721-5925 Fax: 406-721-3859 | |
Ty William Felton, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2230 N Reserve St Ste 330, Missoula, MT 59808 Phone: 406-309-6633 Fax: 406-309-6644 | |
Dr. Kellie Marie Hadnot, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2106 Oxford St, Missoula, MT 59801 Phone: 406-549-2541 | |
Dr. Heidi Gail Brott, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4000 Us Highway 93 S, Missoula, MT 59804 Phone: 406-251-3679 Fax: 406-251-3715 | |
Shopko Optical 075 Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2510 S Reserve St, Missoula, MT 59801 Phone: 406-721-4646 | |
Sandy Sheppard Od Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 700 South Ave W, Ste. G, Missoula, MT 59801 Phone: 406-549-4851 Fax: 406-549-8486 |